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Abstract 
A set of 13 alkyl derivatives of 3-phenylpiperidine-2,6-dione were synthesized. 
Newly obtained compounds were investigated in vitro against HIV-1 and other 
selected viruses. The benzyl 3f  and fluorophenyl 3g derivatives showed 
moderate protection against CVB-2 and the compound 3g also against HSV-1. 
Derivatives were tested also for their antibacterial and antifungal activity. The 
molecular structures of 3a and 3d were determined by an X-ray analysis. 
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Introduction 
Literature survey shows that phenylpiperazinyl group is a nuclei of antiviral, antibacterial 
and antifungal [1–3] agents. It could be integrated with imidazole [4, 5], 1,8-naphthyridone 
[6], furan [7], 1,4-dithiine [8] or quinolone [9] rings. N-alkyl and N-aryl piperazines are also 
present as phosphonate [10] and cyano [11] derivatives. Short-chain p-substituted aryl 
piperazines are found as active against Staphylococcus aureus and Pseudomonas 
aeruginosa [12, 13]. Recently, derivatives of diarylpiperidin-4-one were found as the new 
class of antimicrobial agents with activity against pathogenic bacterial species and fungal 226 A.  Bielenica  et al.:  
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strains [14]. There is also an increasing concern on substituted 4-arylpiperazines, 
4-azatricyclodec-8-ene-3,5-dione derivatives, as some of them have been reported as 
antiviral agents, e.g. against Yellow Fever Virus (YFV) and Border Disease Virus (CVB-2), 
as well as antibacterial and antifungal compounds [1, 15]. Some anti-HIV-1 agents, as 
NNRTIs (non-nucleoside reverse transcriptase inhibitors) possess an arylpiperazine part 
(Atevirdine, Indinavir, Delavirdine and Vicriviroc). Their activity is also connected with the 
presence of pyridinylpiperazine or 2-hydroxypropyl fragments. Literature survey revealed 
that modifications of their structures lead to new potential antiviral drugs [3, 16–19]. 
This work describes synthesis and a wide spectrum of antiviral activity screening of some 
novel 3-phenylpiperidine-2,6-diones. Almost all piperazine derivatives presented in this 
study were tested on anti-HIV-1 activity. Antibacterial and antifungal activity of most of 
newly synthesized compounds was also evaluated. Due to its high 5-HT1A receptor affinity 
and selectivity [20], the derivative 3a was tested for its pharmacological properties in three 
behavioral tests in mice (data not shown). The molecular structures of 3a and 3d were 
determined by an X-ray analysis. 
Results and discussion 
The preparation of new thirteen 3-phenylpiperidine-2,6-dione derivatives is described. The 
general synthetic pathway and structure of the investigated compounds is given in Fig. 2. 
The starting imide 2 was obtained from 2-phenylglutaric anhydride in reaction with 
ammonium carbonate. Next the compound was subjected to the reaction with 1,4-dibromo-
butane and 1,3-dibromopropane in order to be transformed into the corresponding alkyl 
derivatives 3 and 4. Next these compounds were condensed with appropriate amines to 
yield compounds 3a–3g and 4a–4c. Obtained N-substituted derivatives were purified by 
column chromatography. Elemental analysis and 
1H NMR spectra confirmed the identity of 
the product. The molecular structure of 3a and 3d was established by the crystal structure 
analysis (Fig. 1). Moreover, the two crystals are hemihydrates with a high degree of 
isostructurality, viz. they have the same symmetry, similar mode of molecular packing and 
noncovalent interactions. Very characteristic feature is: (a) the O–H…N hydrogen bond 
formed between the water molecule and the piperazine N1-atom, and (b) the lack of 
hydrophobic interactions of both the methoxy group (3a) and pyridine N-atom (3d). 
 
Fig. 1.   Molecular conformation of 3d and the O-H…N hydrogen bond (dashed line) 
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Fig. 2.   Synthesis of 3-phenylpiperidine-2,6-dione derivatives. 228 A.  Bielenica  et al.:  
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Tab. 1.   Cytotoxicity and antiviral activity of compounds 2, 3a–3g and 4a–4d. 
aMT-4 
bHIV-1
cMDBK
dBVDV
eBHK-21
fYFV 
fReo-1 # 
CC50 EC50 CC50 EC50 CC50 EC50 EC50 
2  >100  >100 >100 >100  >100  >100  >100 
3a  >100  >100 >100 >100  >100  >100  >100 
3c  >100  >100 >100 >100  >100  >100  >100 
3d  >100  >100 >100 >100  >100  >100  >100 
3e 74  >74  >100  >100  >100  >100  >100 
3f  >100  >100 >100 >100  >100  >100  >100 
3g 54  >54  >100  >100  >100  >100  >100 
4a  >100  >100 >100 >100  >100  >100  >100 
4b  >100  >100 >100 >100  >100  >100  >100 
4c  >100  >100 >100 >100  >100  >100  >100 
4d  >100  >100 >100 >100  >100  >100  >100 
AZT
§  50 0.01           
NM 108
#       1.8    2.5   
gVero-76 
hHSV-1
hVV 
hVSV 
hCVB-2 
hSb-1
 
# 
CC50 EC50 EC50 EC50 EC50 EC50 
2 98  >98  >98  >98  >98  >98 
3a  >100  >100 >100 >100  >100  >100 
3c >100  >100  >100 >100  >100  >100 
3d 98  >98  >98  >98  >98  >98 
3e  >100  >100 >100 >100  >100  >100 
3f 96  >96  >96  >96  44  >96 
3g 92  31  >92  >92  44  >92 
4a  >100  >100 >100 >100  >100  >100 
4b 98  >98  >98  >98  >98  >98 
4c  >100  >100 >100 >100  >100  >100 
4d  >100  >100 >100 >100  >100  >100 
NM 176*
       23  18 
M 5255**
     1.8      
ACG***   3         
Antiviral activity is given as EC50 (Median Effective Concentration – the concentration of a 
drug (μM) required to induce a 50% effect), and cytotoxicity is given as CC50 (Cytotoxic 
Concentration – the amount of a drug (μM) at which 50% of cells become dead). 
a,c,e,g Compd. concn. (μM) required to reduce the viability of mock-infected MT-4 (CD4
+ 
Human T-cells containing an integrated HTLV-1 genome, 
a) cells or MDBK (Bovine normal 
kidney, 
c) cells or BHK (Hamster normal kidney fibroblast, 
e) monolayers or VERO-76 
(Monkey normal kidney) monolayers by 50%, as determined by the colorimetric MTT 
method. 
b,d,f,h Compd. concentration (μM) required to achieve 50% protection of MT-4 cells from the 
HIV-1-induced cytopathogenicity (
b) or MDBK cells from the BVDV (Bovine Viral Diarrhea 
Virus)-induced cytopathogenicity (
d) or BHK (Kidney fibroblast) cells from the YFV (Yellow 
Fever Virus) and Reo (Reovirus 1)-induced cytopathogenicity (
f) or to reduce the plaque 
number of HSV-1 (Herpesvirus 1), VV (Vaccinia Virus), VSV (Vesicular Stomatitis Virus), 
CVB-2 (Coxsackievirus B2), Sb-1 (Poliovirus 1) and RSV (Respiratory Syncytial Virus) by 
50% in VERO-76 monolayers (
h), as determined by the MTT method. 
§ 3’-azidothymidine; 
# 2’-ß-methylguanosine; * 2’-ethynyl-D-cytidine; ** mycophenolic acid; 
*** acycloGuanosine. 
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For biochemical studies N-substituted alkyl derivatives were converted into their 
hydrochlorides. Compounds 3a and 3d were presented as monohydrochlorides and 3b, 
3c, 3e, 3f, 3g, 4a, 4b, 4d as dihydrochlorides. 
Ten compounds, N-substituted derivatives of 3-phenylpiperidine-2,6-dione, were evaluated 
in vitro against viruses, bacteria and fungi.  
Title compounds were evaluated for antiviral activity against viruses representative of two 
of the three genera of Flaviviridae family, that is, Flaviviruses (Yellow Fever Virus, YFV) 
and Pestiviruses (Bovine Viral Diarrhoea Virus, BVDV), as Hepaciviruses can hardly be 
used in routine cell-based assays. Compounds were also tested against representatives of 
other virus families. Among ssRNA+ were a retrovirus (human immunodeficiency virus 
type 1, HIV-1) and two Picornaviruses (Coxsackie Virus type B2, CVB-2 and Poliovirus 
type-1, Sabin strain, Sb-1); among ssRNA- were a Rhabdoviridae (Vesicular Stomatitis 
Virus, VSV) representative. Among double-stranded RNA (dsRNA) viruses was a 
Reoviridae representative (Reo-1). Two representatives of DNA virus families were also 
included: Herpes Simplex type-1, HSV-1 (Herpesviridae) and Vaccinia Virus, VV 
(Poxviridae). 
In addition to the antiviral activity, compounds were evaluated in vitro against 
representative strains of Gram-positive and Gram-negative bacteria (Staphylococcus 
aureus, Pseudomonas aeruginosa), yeasts and moulds (Candida albicans and Aspergillus 
niger). 
AZT (3’-azidothymidine), NM 108 (2’-ß-methylguanosine), NM 176 (2’-ethynylcitidine), M 
5255 (Mycophenolic Acid) and ACG (acycloGuanosine) were used as reference inhibitors 
of ssRNA+, ssRNA- and DNA viruses, respectively. 
Two of tested derivatives presented moderate antiviral activity (Table 1). The CVB-2 cells 
were susceptible to benzyl (3f) and 1-(4-fluorophenyl)-substituted (3g) long-chain 
arylpiperazine derivatives. The fluorophenyl derivative was also active against HSV-1 
virus. The 50% cytotoxic concentration (CC50) of this compound in Vero-76 cells was 92 
µM. The range of cytotoxicity of compounds in MT-4 cells was from 100 to 54 µM.  
Tab. 2.   Antibacterial and antifungal activities of 3-phenylpiperidine-2,6-dione and its 
derivatives. 
MIC
a [μM] 
  S. aureus 
DSM 2569 
P. aeruginosa 
DSM 1117 
C. albicans 
DSM 1386 
A. niger 
DSM 1988 
2, 3a, 3c–3g, 4a–4d >100  >100  >100  >100 
Ciprofloxacin
b 4  0.8  –  – 
Miconazole
b –  –  0.8  20 
a The antimicrobial activity is given as Minimum inhibitory concentration (MIC) corresponding to the 
lowest concentration of an antimicrobial compound that showed complete growth inhibition. 
b Ciprofloxacin was solubilized in water (0.1 M solution) and Miconazole in DMSO (0.1 M solution), 
according to the British Society for Antimicrobial Chemotherapy (BSAC) protocol and stored at 4°C 
overnight. Reference Compounds were diluted from 100 to 0.0013 μM. 
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Gram-negative rods as well as gram-positive strains and fungal organisms were resistant 
to all tested agents. Their minimal inhibitory concentration (MIC) values for all compounds 
were above 100 µM (Table 2). However, none of title compounds turned out to be active 
against HIV-1, BVDV or representatives of ssRNA- and dsRNA viruses.  
Theoretical calculated lipophilicity (logP) of synthesized compounds ranged from 1.89 to 
3.92. According to Clark and Lobell rules [21], all derivatives could cross the blood-brain 
barrier to act as ligands of receptors of central nervous system.  
Experimental 
Chemistry 
All chemicals and solvents were purchased from Aldrich (Vienna, Austria). Melting points 
were determined on an Electrothermal Digital Melting Point Apparatus (Essex, UK) and 
are uncorrected. The 
1H-NMR spectra were recorded on a Bruker (Rheinstetten, 
Germany) spectrometer, operating at 400 or 300 MHz. The chemical shift values are 
expressed in ppm relative to TMS as an internal standard. Elemental analyses were 
recorded on a CHN model 2400 Perkin-Elmer (Hitachi, Tokyo, Japan). TLC was carried 
out using silica gel 60 F254, layer thickness 0.25 mm (E. Merck, Darmstadt, Germany) and 
the results were visualized using UV lamp at 254 nm. Column chromatography was carried 
out using silica gel 60 (200–400 mesh, Merck).  
The elemental analyses and 
1H-NMR spectra, as well as melting points are given for 
dihydrochlorides (except for compounds 3, 4, 3a and 3d). Yields are presented for crude 
products. 
LogP values for arylpiperazine derivatives were calculated using ChemBioDrawUltra 12.0. 
(http://www.cambridgesoft.com). 
Molecular structure of 3a and 3d was confirmed by an X-ray crystallography (Table 3). The 
intensity data were collected at room temperature with a KM4 diffractometer using graphite 
monochromated CuKα radiation (λ = 1.54178 Å) and ω – 2θ scan mode. Both compounds 
crystallized as hemihydrates and their crystals were of poor quality. Structure was solved 
by the SHELXS-97 program and refined by full-matrix least-squares on F
2 using the 
SHELXL-97 program [18]. Non-hydrogen atoms were refined with anisotropic 
displacement parameters, except those of phenyl rings of 3a. The H-atoms of molecules 
3a and 3d were positioned geometrically and ‘riding’ model was used in the refinement, 
while H-atoms of water molecules were located on difference maps. Crystallographic data 
had been deposited with the Cambridge Crystallographic Data Center.  
3-Phenylpiperidine-2,6-dione (2) 
A mixture of 2-phenylglutaric anhydride (0.0165 mol) and (NH4)2CO3 (0.125 mol) was 
reduced to powder and heated up to 185 °C using a metal bath of Wood's alloy. When 
CO2 and NH3 were completely liberated, 10 cm
3 of paraffin oil was added and whole 
mixture was heated until the evolution of gas ceased. The residue was crystallized from 
hexane and ethyl acetate; mp 143 °C (mp 142–143 from methanol [23]).  
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Tab. 3.   Crystal data and parameters of the data collection and refinement for crystals of 
3a⋅½ H2O and 3d⋅½ H2O. 
Identification code   3a⋅½ H2O 3d⋅½ H2O 
No CCDC*  770 127  770 128 
Formula weight   444.56  415.53 
Crystal system   monoclinic monoclinic 
Space group   C2  C2 
Unit cell dimensions 
a (Å) 
 
26.891(5)  
 
18.908(4) 
b (Å)  6.344(1)  6.244(1)  
c (Å)  18.631(4)  19.087(4)  
β (°)  129.05(3) 93.56(3) 
Volume (Å
3); Z  2468.3(8); 4   2249.1(8); 4  
Density (calc) (g cm
−3)  1.196   1.227  
Absorption coeff. (mm
−1) 0.639    0.646 
F(000) 956  892 
Crystal size (mm)  0.28 x 0.12 x 0.05   0.22 x 0.20 x 0.04  
Theta range for data collection (°)  3.05 to 70.16  4.69 to 72.13 
Index ranges  -32 ≤ h ≤ 32, -7 ≤ k ≤ 7, 
-16 ≤ l ≤ 22 
-23 ≤ h ≤ 23, -7 ≤ k ≤ 7, 
-23 ≤ l ≤ 0 
Reflections collected  4852  4462 
Independent reflections  4436 [R(int) = 0.1722]  4328 [R(int) = 0.0489] 
Data / restraints / parameters  4436 / 1 / 223  4328 / 1 / 276 
Goodness-of-fit on F2  1.000 0.942 
Final R indices [I >2s (I)]  R1 = 0.0787,  
wR2 = 0.2201 
R1 = 0.0380,  
wR2 = 0.0961 
Δρ max.; min. (e Å
-3)  0.25; -0.29  0.18; -0.18  
These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk. 
 
General method for preparation of 1-(alkyl)-3-phenylpiperidine-2,6-diones 3 and 4 
A mixture of imide 2 (1.5 g, 0.008 mol), 1,4-dibromobutane (0.02 mol) and 1,3-dibromo-
propane (0.02 mol), respectively, anhydrous K2CO3 (1.5 g) and catalytic amount of 98% 
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) were refluxed in acetone for 60–70 h. Then, the 
solvent was removed on a rotary evaporator and the oily residue was purified by column 
chromatography (chloroform : methanol 9.5:0.5 vol). 
1-(4-Bromobutyl)-3-phenylpiperidine-2,6-dione (3)  
Yield: 78%, mp 138.5–140 °C. 
1H NMR (400 MHz, CDCl3, TMS): δ 7.32 (m, 5H, ArH), 3.85 
(m, 3H), 3.43 (t, J = 6.4 Hz, 2H), 2.72 (m, 2H), 2.22 (m, 2H), 1.88 (m, 2H), 1.73 (m, 2H). 
Anal. Calcd. for C15H18BrNO2: C, 55.57; H, 5.60; N, 4.32. Found: C, 55.47; H, 5.61; N, 
4.33. 
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1-(3-Bromopropyl)-3-phenylpiperidine-2,6-dione (4)  
Yield: 75%, oil. 
1H NMR (400 MHz, CDCl3, TMS): δ 7.34 (m, 4H), 7.17 (d, J = 7.6 Hz, 1H), 
3.98 (t, J = 6.8 Hz, 2H), 3.84 (dd, J1 = 5.6 Hz, J2 = 8.8 Hz), 3.40 (t, J = 6.8 Hz, 2H), 2.73 
(m, 2H), 2.26 (m, 2H), 2.17 (m, 2H). Anal. Calcd. for C14H16BrNO2: C, 54.21; H, 5.20; N, 
4.52. Found: C, 54.47; H, 5.24; N, 4.55. 
General method for the preparation of 1-[4-aryl/heteroarylpiperazin-1-ylbutyl)  
(3a–3g) and 1-[3-aryl/heteroarylpiperazin-1-ylpropyl) (4a–4c) derivatives of 3-phenyl-
piperidine-2,6-dione 
A mixture of derivative 3 (0.3 g, 0.001 mol) and 4 (0.3 g, 0.001 mol), respectively, the 
corresponding amine (0.002 mol), anhydrous K2CO3 (0.3 g) and catalytic amount of KI was 
refluxed in acetone for 30 h. Then the mixture was filtered off and the solvent was 
evaporated. The residue was purified by column chromatography (chloroform : methanol 
9.5:0.5 vol) and/or crystallized from hexane.  
Obtained compounds were converted into their hydrochlorides. The solid product was 
dissolved in methanol saturated with gaseous HCl. The hydrochloride was precipitated by 
addition of diethyl ether. The crude product was crystallized from methanol/ethyl ether. 
1-{4-[4-(2-Methoxyphenyl)piperazin-1-yl]butyl}-3-phenylpiperidine-2,6-dione (3a)  
Mp 210 °C from acetone (mp (salt) from acetone 209–210 °C) [20]. LogP = 3.64.  
3-Phenyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione (3b) 
Yield: 70%, mp 210–212 °C. 
1H NMR (400 MHz, CDCl3, TMS): δ 8.30 (d, J = 4.8 Hz, 2H), 
7.33 (m, 3H), 7.17 (d, J = 7.2 Hz, 2H), 6.48 (t, J = 4.8 Hz, 1H), 3.85 (m, 7H), 2.72 (m, 2H), 
2.52 (m, 4H), 2.43 (m, 2H), 2.22 (m, 2H), 1.60 (m, 4H). Anal. Calcd. for C23H29N5O2 ⋅ 2HCl 
⋅ ½ H2O: C, 55.34; H, 6.76; N, 14.67. Found: C, 55.07; H, 6.72; N, 14.87. LogP = 2.34. 
1-{4-[4-(2-Hydroxyphenyl)piperazin-1-yl]butyl}-3-phenylpiperidine-2,6-dione (3c)  
Yield: 67%, mp 234–236 °C. 
1H NMR (300 MHz, DMSO, TMS): δ 7.30 (m, 5H), 6.91 (m, 
3H), 6.77 (t, J = 7.2 Hz, 1H), 5.20 (m, 6H), 4.00 (dd, J1 = 4.8 Hz, J2 = 11.2 Hz, 1H), 3.72 (t, 
J = 6.8 Hz, 2H), 3.14 (m, 4H), 2.82 (m, 1H), 2.65 (m, 1H), 2.23 (m, 1H), 2.06 (m, 1H), 1.73 
(m, 2H), 1.73 (t, J = 6.8 Hz, 2H). Anal. Calcd. for C25H31N3O3 ⋅ 2HCl ⋅ ½ H2O: C, 59.64; H, 
6.81; N, 8.35. Found: C, 59.51; H, 6.71; N, 8.31. LogP = 3.37. 
3-Phenyl-1-[4-(4-pyridin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione (3d)  
Yield: 62%, mp 102–104 °C. 
1H NMR (400 MHz, CDCl3, TMS): δ 8.19 (m, 1H), 7.47 (t, J = 
7.2 Hz, 1H), 7.33 (m, 4H), 7.17 (d, J = 7.2 Hz, 1H), 6.63 (m, 2H, pyridine), 3.84 (m, 3H), 
3.59 (m, 4H), 2.75 (m, 2H), 2.60 (m, 4H), 2.46 (m, 2H), 2.23 (m, 2H), 1.61 (m, 4H). Anal. 
Calcd. for C24H30N4O2 ⋅ 2HCl ⋅ 2H2O: C, 55.92; H, 7.04; N, 10.87. Found: C, 56.09; H, 
6.74; N, 10.55. LogP = 3.14. Crystal data: C24H30N4O2 · ½ H2O, crystal system monoclinic, 
space group C2 with unit cell dimensions: a = 18.908(4) Å, b = 6.244(1) Å, c = 19.087(4)= 
Å, β = 93.56(3)°, V = 2249.1(8)Å
3, Z = 4, D(calcd) = 1.227 g/cm
3. Independent reflections 
4328, final R indices [for 1293 reflections with I > 2σ (I)] R1 = 0.038, wR2 = 0.0961. 
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3-Phenyl-1-[4-(4-phenylpiperazin-1-yl)butyl]piperidine-2,6-dione (3e) 
Yield: 60%, mp 177–179 °C. 
1H NMR (400 MHz, CDCl3, TMS): δ 7.17 (m, 10H, ArH), 3.85 
(m, 3H, CH2-1’ and H-3), 3.22 (m, 4H, piperidine, H-2,6), 2.74 (m, 2H, CH2-4’), 2.63 (m, 
4H, piperidine, H-3,5), 2.45 (m, 2H, H-4), 2.20 (m, 2H, H-5), 1.60 (m, 4H, CH2-2’ and CH2-
3’). Anal. Calcd. for C25H31N3O2 ⋅ 2HCl ⋅ H2O: C, 60.48; H, 7.11; N, 8.47. Found: C, 60.31; 
H, 6.79; N, 8.37. LogP = 3.76. 
1-[4-(4-Benzylpiperazin-1-yl)butyl]-3-phenylpiperidine-2,6-dione (3f) 
Yield: 55%, mp 248–250 °C. 
1H NMR (300 MHz, DMSO, TMS): δ 7.64 (m, 2H, Ar, H-3,5), 
7.46 (m, 3H, Ar, H-2,4,6), 7.30 (m, 5H, ArH), 4.36 (br.s, 2H, CH2-1’), 4.00 (dd, J1 = 4.8 Hz, 
J2 = 11.2 Hz, 1H, H-3), 3.67 (m, 10H, piperidine, H-2,3,5,6 and H-4), 3.09 (m, 2H, CH2-4’), 
2.80 (m, 1H, CH2-Ar), 2.63 (m, 1H, H-4), 2.19 (m, 1H, H-5), 2.03 (m, 1H, H-5), 1.67 (m, 2H, 
CH2-3’), 1.50 (m, 2H, CH2-2’). Anal. Calcd. for C26H33N3O2 ⋅ 2HCl ⋅ ½ H2O: C, 62.27; H, 
7.24; N, 8.38. Found: C, 62.58; H, 6.92; N, 8.47. LogP = 3.42. 
1-{4-[4-(4-Fluorophenyl)piperazin-1-yl]butyl}-3-phenylpiperidine-2,6-dione (3g) 
Yield: 73%, mp 178–180 °C. 
1H NMR (300 MHz, DMSO, TMS): δ 7.12 (m, 9H), 4.00 (dd, 
J1 = 4.8 Hz, J2 = 11.2 Hz, 1H), 3.70 (m, 4H), 3.50 (m, 2H), 3.14 (m, 7H), 2.81 (m, 1H), 2.64 
(m, 1H), 2.22 (m, 1H), 1.74 (m, 2H), 1.50 (t, J = 7.2 Hz, 2H). Anal. Calcd. for C25H30FN3O2 
⋅ 2HCl ⋅ ¾ H2O: C, 58.88; H, 6.62; N, 8.24. Found: C, 58.86; H, 6.35; N, 8.16. LogP = 3.92. 
1-{3-[4-(2-Methoxyphenyl)piperazin-1-yl]propyl}-3-phenylpiperidine-2,6-dione (4a)  
Yield: 63%, mp 178–180 °C. 
1H NMR (400 MHz, CDCl3, TMS): δ 7.33 (m, 3H), 7.18 (d, J = 
7.6 Hz, 2H), 7.01 (m, 1H), 6.93 (t, J = 6.8 Hz, 2H), 6.86 (m, 1H), 3.93 (t, J = 6.8 Hz, 2H), 
3.85 (m, 4H), 3.20 (m, 4H), 2.74 (m, 8H), 2.24 (m, 2H), 1.93 (m, 2H). Anal. Calcd. for 
C25H31N3O3 ⋅ 2HCl ⋅ 2H2O: C, 65.60; H, 7.03; N, 7.92. Found: C, 56.87; H, 6.69; N, 8.08. 
LogP = 3.18. 
3-Phenyl-1-[3-(4-pyrimidin-2-ylpiperazin-1-yl)propyl]piperidine-2,6-dione (4b)  
Yield: 60%, mp 214–216 °C. 
1H NMR (400 MHz, CDCl3, TMS): δ 8.32 (d, J = 4.8 Hz, 2H), 
7.33 (m, 3H), 7.18 (d, J = 7.2 Hz, 2H), 6.52 (t, J = 4.0 Hz), 3.88 (m, 7H), 2.76 (m, 8H), 2.23 
(m, 2H)  , 1.96 (m, 2H). Anal. Calcd. for C22H27N5O2 ⋅ 2HCl ⋅ ½ H2O: C, 55.58; H, 6.36; N, 
14.73. Found: C, 55.43; H, 6.40; N, 14.59. LogP = 1.89. 
1-{3-[4-(2-Hydroxyphenyl)piperazin-1-yl]propyl}-3-phenylpiperidine-2,6-dione (4c)  
Yield: 65%, mp 158–160 °C. 
1H NMR (400 MHz, CDCl3, TMS): δ 7.33 (m, 3H), 7.17 (m, 
3H), 7.07 (t, J = 7.6 Hz, 1H), 6.94 (d, J = 7.6 Hz), 6.85 (t, J = 7.6 Hz, 1H), 3.93 (t, J = 7.2 
Hz, 2H), 3.88 (dd, J1 = 5.2 Hz, J2 = 8.8 Hz, 1H), 3.01 (m, 4H), 2.76 (m, 8H), 2.24 (m, 2H), 
1.91 (m, 2H). Anal. Calcd. for C24H29N3O3 ⋅ HCl ⋅ 2 ½ H2O: C, 58.95; H, 7.21; N, 8.59. 
Found: C, 59.45; H, 6.84; N, 8.33. LogP = 2.92. 
3-Phenyl-1-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]piperidine-2,6-dione (4d)  
Yield: 70%, mp 116–118 °C. 
1H NMR (400 MHz, CDCl3, TMS): δ 8.19 (d, J = 3.2 Hz, 1H), 
7.47 (m, 1H), 7.32 (m, 3H), 7.17 (d, J = 7.2 Hz, 2H), 6.63 (m, 2H), 3.92 (t, J = 7.6 Hz, 2H), 
3.84 (dd, J1 = 5.2 Hz, J2 = 9.2 Hz, 1H), 3.56 (m, 4H), 2.72 (m, 2H), 2.58 (m, 4H), 2.47 (t, J 234 A.  Bielenica  et al.:  
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= 6.8 Hz, 2H), 2.21 (m, 2H), 1.83 (m, 2H). Anal. Calcd. for C23H28N4O2 ⋅ 2HCl ⋅ 2H2O: C, 
55.09; H, 6.83; N, 11.17. Found: C, 55.48; H, 6.54; N, 10.97. LogP = 2.69. 
Microbiological assays 
Compounds 
Compounds were dissolved in DMSO at 100 mM and then diluted in culture medium. 
Cells and Viruses 
Cell lines were purchased from American Type Culture Collection (ATCC). The absence of 
mycoplasma contamination was checked periodically by the Hoechst staining method. Cell 
lines supporting the multiplication of RNA viruses were the following: CD4
+ human T-cells 
containing an integrated HTLV-1 genome (MT-4); Madin Darby Bovine Kidney (MDBK); 
Baby Hamster Kidney (BHK-21) and Monkey kidney (Vero 76) cells. 
Bacterial strains 
The antibacterial activity of compounds was tested against collection strains representative 
of Gram-positive bacteria (Staphylococcus aureus DSM 2569) and Gram-negative bacteria 
(Pseudomonas aeruginosa DSM 1117). Antifungal activity was tested against collection 
strains representative of yeasts (Candida albicans DSM 1386) and moulds (Aspergillus 
niger DSM 1988). 
Cytotoxicity Assays 
For cytotoxicity tests, run in parallel with antiviral assays, MDBK, BHK and Vero 76 cells 
were resuspended in 96 multiwell plates at an initial density of 6 x 10
5, 1 x 10
6 and 5 x 10
5 
cells/mL, respectively, in maintenance medium, without or with serial dilutions of tested 
compounds. Cell viability was determined after 48–120 hrs at 37 °C in a humidified CO2 
(5%) atmosphere by the MTT method. The cell number of Vero 76 monolayers was 
determined by staining with the crystal violet dye. 
For cytotoxicity evaluations, exponentially growing cells derived from human 
haematological tumors [CD4
+ human T-cells containing an integrated HTLV-1 genome 
(MT-4)] were seeded at an initial density of 1 x 10
5 cells/mL in 96 well plates in RPMI-1640 
medium, supplemented with 10% fetal calf serum (FCS), 100 units/mL penicillin G and 100 
µg/mL streptomycin. Cell cultures were then incubated at 37 °C in a humidified, 5% CO2 
atmosphere in the absence or presence of serial dilutions of test compounds. Cell viability 
was determined after 96 hrs at 37  °C by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) method [24]. 
Antiviral assay 
Activity of compounds against Human Immunodeficiency virus type-1 (HIV-1) was based 
on inhibition of virus-induced cytopathogenicity in MT-4 cells acutely infected with a 
multiplicity of infection (m.o.i.) of 0.01. Briefly, 50 μL of RPMI containing 1x10
4
 MT-4 were 
added to each well of flat-bottom microtitre trays containing 50 μL of RPMI, without or with 
serial dilutions of test compounds. Then, 20 μL of an HIV-1 suspension containing 100   Synthesis and Biological Evaluation of 3-Phenyl-1-[(4-arylpiperazin-1-yl)alkyl]piperidine-2,6-diones 235 
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CCID50 were added. After a 4-day incubation, cell viability was determined by the MTT 
method. 
Activity of compounds against Yellow Fever Virus (YFV) and Reo virus type-1 (Reo-1) was 
based on inhibition of virus-induced cytopathogenicity in acutely infected BHK-21 cells. 
Activities against Bovine Viral Diarrhoea Virus (BVDV), in infected MDBK cells, were also 
based on inhibition of virus-induced cytopathogenicity. 
BHK and MDBK cells were seeded in 96-well plates at a density of 5 x 10
4 and 3 x 10
4 
cells/well, respectively, and were allowed to form confluent monolayers by incubating 
overnight in growth medium at 37  °C in a humidified CO2 (5%) atmosphere. Cell 
monolayers were then infected with 50 µL of a proper virus dilution (in serum-free medium) 
to give an m.o.i = 0.01. 1 hr later, 50 µL of MEM Earle’s medium, supplemented with 
inactivated foetal calf serum (FCS), 1% final concentration, without or with serial dilutions 
of test compounds, were added. After 3-4 days of incubation at 37 °C, cell viability was 
determined by the MTT method. 
Activity of compounds against Coxsackie virus, B-2 strain (CVB-2), Polio virus type-1 
(Polio-1), Sabin strain, Vesicular Stomatitis Virus (VSV), Vaccinia Virus (VV) and Herpes 
Simplex Virus type-1 (HSV-1), in infected Vero 76 cells, was determined by plaque 
reduction assays in Vero 76 cell monolayers. To this end, Vero 76 cells were seeded in 
24-well plates at a density of 2 x 10
5 cells/well and were allowed to form confluent 
monolayers by incubating overnight in growth medium at 37 °C in a humidified CO2 (5%) 
atmosphere. Then, monolayers were infected with 250 µL of proper virus dilutions to give 
50-100 PFU/well. Following removal of unadsorbed virus, 500 µL of Dulbecco’s modified 
Eagle’s medium, supplemented with 1% inactivated FCS and 0.75% methyl cellulose, 
without or with serial dilutions of test compounds, were added. Cultures were incubated at 
37 °C  for  2 (Sb-1 and VSV) or 3 (CVB-2, VV and HSV-1) and then fixed with PBS 
containing 50% ethanol and 0.8% crystal violet, washed and air-dried. Plaques were then 
counted. 50% effective concentrations (EC50) were calculated by linear regression 
technique. 
Antibacterial and antifungal assays 
The antibacterial and antifungal activities were evaluated by determining the Minimum 
inhibitory concentration (MIC) by the broth microdilution procedure.  
Bacterial strains were grown on Tryptic soy agar at 37 °C for 1 day. Cell suspensions of 
these recent cultures were prepared in sterile 0.85% saline solution by 4–5 colonies. The 
turbidity of the suspensions was adjusted to the McFarland 0.5 standard. Suspensions 
were diluted in cation-supplemented Mueller-Hinton broth. For each microorganism, 
100 µL of the fivefold serial dilutions of the compounds in cation-supplemented Mueller-
Hinton broth and 100 µL of inoculum were added to each well of a microdilution plate (final 
titre 5 x 10
5 CFU/mL). The inoculated plates were incubated at 37 °C in non-CO2 incubator 
and humid atmosphere. The MICs were determined after 16–20 h [25]. 
Fungal strains were grown on Sabouraud’s dextrose agar at 35  °C for 1–5 days. 
Suspensions of these recent cultures were prepared in sterile saline solution (NaCl 
0.85%). Suspensions were then diluted in Sabouraud’s dextrose broth. 100 µL of the 236 A.  Bielenica  et al.:  
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fivefold serial dilutions of the compounds in Sabouraud’s dextrose broth and 100 µL of 
inoculum were added to each well of a microdilution plate (C. albicans 1 x 10
4 cell/mL; A. 
niger OD600 0.05). The inoculated plates were incubated at 35 °C in non-CO2 incubator 
and humid atmosphere. The MICs were determined after 24 and 48 h. 
The concentration of each inoculum was confirmed by viable counts on agar plates by 
plating the appropriate dilution of the growth control well, immediately after inoculation, 
and incubating until visible growth. MIC corresponded to the lowest concentration of an 
antimicrobial compound that showed complete growth inhibition. 
Linear regression analysis 
Viral and cell growth at each drug concentration was expressed as percentage of 
untreated controls and the concentrations resulting in 50% (EC50, CC50) growth inhibition 
were determined by linear regression analysis. 
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